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============

Over the past 25 years, autoimmune diagnostics has gone through an evolutionary period, which seems not yet ended, as clinical and basic knowledge in the field of autoimmunity is still growing. From year to year, important achievements in pathophysiology, development of new diagnostic technologies and advances in therapy of autoimmune diseases (AIDs) have been steadily added. The engine of this evolutionary period is the improvement in AIDs diagnostics, which has allowed an increasing number of recognized cases of individuals (3--8 % of the population; 80 % women) suffering from one or more AIDs \[[@CR1], [@CR2]\]. The main recent cornerstones in this field have been: (a) The discovery of new autoantibody-autoantigen systems (both systemic and organ-specific); (b) Recognition that autoantibodies may have predictive, pathogenic, or protective roles; (c) The availability of new diagnostic technologies (monoplex and multiplex immunoassays-IMA), and (d) Changes in organizational processes (integration and automation) \[[@CR3]--[@CR6]\].

We could now wonder if such events could have been foreseen at the beginning of the era of modern autoimmune diagnostics. The answer to this question lies in the expected changes in clinical immunology laboratories as dictated in the early 1990s. Twenty years ago, Nakamura and Bylund \[[@CR7]\], during the 17th AO Beckman conference, identified the primary focus of the laboratory of clinical immunology and defined the main influencing factors of future changes: governmental regulations, healthcare economics, advances in technology and advances in development and use of therapeutic agents. At the same time, Hamilton \[[@CR8]\], looking at the clinical immunology laboratory of the future, emphasized the importance of standardization of methods and development of 'universal' automated immunoanalyzers. Two years later, Normansell \[[@CR9]\], at the 8th annual meeting of the American Association of Medical Laboratory Immunologists, foresaw the progressive unification of academic specialty laboratories (chemistry, hematology, immunology, etc.) in a unique general laboratory (consolidation).

Most of these predictions have been achieved, and especially automation and consolidation paved the way to the modern laboratory \[[@CR10], [@CR11]\]. During the past decade, we and others \[[@CR12]--[@CR16]\] have described the progressive evolution of analytical methods and technologies, signaling the extraordinary dynamic development of autoimmune diagnostics resulting from the availability of new tests, diffusion of improved immunoassay methods and instruments, and the explosive growth of molecular biology and proteomic medicine.

To meet both clinical need and growing demand for autoantibody testing, automation of autoimmune diagnostics has invaded the laboratory as an extension of the general technological improvement already achieved in almost all other diagnostic areas of the clinical laboratory \[[@CR17], [@CR18]\]. Currently, all stages of the analytical procedure for detection and quantification of autoantibodies are automated. The third generation of laboratory systems now encompasses most of the analytical steps of the laboratory workflow, enabling the clinical pathologists (autoimmunologists in this case) to focus on 'value-added' work, such as result validation and production of narrative reports for clinical interpretation \[[@CR4]\].

The two key concepts of third generation systems are 'consolidation' (i.e., combining different analytical technologies or strategies on one instrument or on one group of connected instruments) and 'integration' (linking analytical instruments or group of instruments with pre- and post-analytical devices).

As predicted, in many cases this approach has brought about the reunification of diagnostics in the central general laboratory. It is now customary to manage the flow of highly demanded autoantibody tests (thyroperoxidase, thyroglobulin, tissue transglutaminase, citrullinated peptide autoantibodies) in 'human-less' robotic platforms, characterized by total laboratory automation (TLA) which includes pre-analytical, analytical, and post-analytical operations \[[@CR19]\]. The rationale in favor of this approach lies in the advantage of placing as many assays on a single analyzer, rather than maintaining two or more analyzers, because each instrument requires separate quality control (QC), preventive maintenance, record keeping, etc. (Figure [1](#Fig1){ref-type="fig"}). TLA combines a large variety of processes, including accessioning and sorting specimens, decapping tubes, centrifugation, aliquoting, delivery to analyzers, recapping tubes, and storage and archiving of samples. The prototype of instruments used in the autoimmunology laboratories is IMA platforms \[[@CR4]--[@CR6]\].Fig. 1Evolution of clinical immunology laboratories

The advantages of TLA include harmonization of testing to improve patient care \[[@CR20]\], reduction of human error, reduction of handling steps, increase of productivity, decrease and standardization of turnaround time (TAT), improvement of safety, use of state of the art informatics (i.e., interface with laboratory information systems-LIS and health information systems; middleware to bridge the analyzers and LIS). Most, if not all, the obstacles to automation as defined by Tomar as much as 15 years ago \[[@CR10]\] are now completely removed.

In the next sections of this article, we present some models related to the introduction of automation in the autoimmunology laboratory: a. automated indirect immunofluorescence (IIF) and the changes in the two-step strategy for detection of autoantibodies, b. automated monoplex IMAs and the reduction of TAT, and c. automated multiplex IMAs and autoantibody profiling.

Automated indirect immunofluorescence and changes in the two-step strategy for autoantibody detection {#Sec2}
-----------------------------------------------------------------------------------------------------

Recently, indirect immunofluorescence (IIF) automation for reading and interpretation of ANA and other autoantibodies was developed, supported by the American College of Rheumatology recommendation that IIF is the reference method for anti-nuclear-cytoplasmic antibodies (NCA or ANA) \[[@CR21], [@CR22]\], anti-neutrophil cytoplasmic antibodies (ANCA) \[[@CR23]\], and anti-dsDNA antibodies (DNAAb). At present, at least 6 automatic systems for the detection of these autoantibodies are available \[[@CR4], [@CR24], [@CR25]\] (Table [1](#Tab1){ref-type="table"}). These systems allow for automated classification of samples, with a high efficiency in discriminating between positive and negative ANA and an acceptable correlation with manual microscope reading \[[@CR4], [@CR26], [@CR27]\], automated quantification of autoantibodies \[[@CR28], [@CR29]\], and implementation of a quantitative internal QC system \[[@CR30]\].Table 1Currently available automated IIF platforms (*H* homogeneous, *S* speckled, *N* nucleolar, *C* centromere, *ND* nuclear dots, *NM* nuclear membrane, *Cy* cytoplasmic)SystemScreening neg/posPatterns (no; type)CompanyAklidesYes6-H, S, N, C, ND, CyMedipan, GermanyEUROPatternYes7-H, S, N, C, ND, NM, CyEuroimmun, GermanyZenit G-SightYes5-H, S, N, C, MA. Menarini Diagnostics, ItalyNOVA viewYes5-H, S, N, C, NDInstrumentation Laboratories, SpainHeliosYes--Aesku Diagnostics, GermanyImage navigatorYes--ImmunoConcepts, USA

These features allow a different approach to the diagnostic strategy for the detection of NCA-ANA, ANCA, and DNAAb, based on a two-step algorithm: the first stage, the screening of positive/negative and positive samples selection; the second stage, identification of specific antibodies for confirmation of screening results and classification of autoimmune diseases \[[@CR33], [@CR34]\].

This flow of information in autoimmune diagnostics has long been conducted with the strategy of reflective testing. That is, the morphologist identifies positive samples using the IIF method and, on the basis of the fluorescence pattern, decides which autoantibodies are to be detected by IMA methods. Moreover, if necessary, reflective testing provides for the addition of new tests beyond the test originally requested and/or production of comments to aid in the correct interpretation of results by the clinical autoimmunologist. Reflective testing can be now replaced with reflex testing, in which a predetermined test protocol is automatically completed \[[@CR35]\]: the integration and the use of specific health information technologies allow now the automated application of rules and the computerized addition of specific tests with high efficiency and effectiveness (Table [2](#Tab2){ref-type="table"}), reducing the need of morphologists and the TAT for clinical applications.Table 2Time evolution of two-step strategy for NCA/ANA detection/measurementEraYearsMethodsManual ANA IIF--reflective adding on--manual ENA1970--2000Manual IIF\
Manual monoplex methods\
Low automated monoplex methodsManual ANA IIF--reflective adding on--automated ENA2000--2014Manual IIF\
Full automated monoplex methods\
Low automated multiplex methodsAutomated ANA IIF--reflex adding on--automated ENA2015--...Automated IIF\
Full automated monoplex methods\
Full automated multiplex methodsFor the terminology see text

Automation of IIF and the use of specific health information technology systems applied to the autoimmunology laboratory, besides allowing for the automated classification of negative/positive results, permit also the practice of pathology at a distance (telepathology, or digital microscopy, or whole slide imaging). Telepathology allows the remote interpretation of fluorescence patterns (telediagnosis), second opinions or consultations (teleconsultation), quality assurance, education, teaching, self-study and research (teleeducation) \[[@CR31]\]. Telepathology has been successfully applied to anatomic pathology, hematology, and microbiology; its use in biomedicine is rapidly evolving \[[@CR32]\].

Monoplex immunoassays and the reduction of turnaround time {#Sec3}
==========================================================

Automated IIF and third-generation monoplex IMAs allow the rapid detection of autoantibodies in terms of minutes or hours, instead of days or weeks as required by manual IIF and IMA methods. In the past, fast autoantibody results did not represent a main goal for clinicians and autoimmunologists, which in many cases utilized longer turnaround times for repetition of positive tests or for second opinions. In current practice, however, life-threatening autoimmune conditions or autoimmune diseases associated with rapidly progressive loss of organ function have emerged, requiring a short response time to allow rapid etiological and differential diagnosis. This, in turn, will enable the start of immunosuppressive or other specific therapies as soon as possible. This is the case, for example, for ANCA-associated small-vessel vasculitides or Goodpasture' syndrome \[[@CR36]\], or for patients with acute cardiovascular symptoms (thyroid storm, atrial fibrillation, supraventricular tachycardia, etc.) in undiagnosed TSH-receptor antibody-dependent Graves' disease \[[@CR37], [@CR38]\]. Another condition involves patients affected by catastrophic anti-phospholipid syndrome with concurrent thrombotic and hemorrhagic manifestations \[[@CR39]\]. In these clinical settings such as may occur in intensive-care units, the rapid availability of autoantibody tests is a great opportunity for early diagnosis and treatment to save a patient's life \[[@CR40]\].

Furthermore, the availability of automated analyzers with reduced assay times (within 120 min) as well of manual point-of-care systems \[[@CR41]\] enables real-time antibody measurement in the same day of the request or even in *stat mode*, avoiding delay and improving compliance towards diagnosis, differential diagnosis and therapy monitoring in the clinical conditions listed above \[[@CR41]\]. This also responds to the increasing need for faster diagnosis owing to shorter period of hospitalization. A partial list of automated platforms, with their assay times and throughput, is shown in Table [3](#Tab3){ref-type="table"}.Table 3Automated monoplex IMA platformsPlatform familyManufacturerAutoantibodies detected (no.)Total assay time (min)Throughput (tests per hour)CentaurSiemens Healthcare Diagnostics, Germany329240ImmuliteSiemens Healthcare Diagnostics, Germany477200MaglumiSNIBE Diagnostic, China835180CobasRoche, Germany318170ArchitectAbbott, USA429100KryptorBrahms, Germany31960BioFlashInstrumentation Laboratory, Spain323060PhadiaThermofisher, Sweden4711060

Automated multiplex IMAs and autoantibody profiling {#Sec4}
===================================================

Multiplex proteomic technology is considered to be an optimal solution for the simultaneous detection of different autoantibodies related to AIDs. Some of these immunoassays (planar and non-planar microarrays) may contribute to overcoming some drawbacks of the monoplex immunoassays (time expenditure, costs, lack of harmonization, volume of reagents and samples, turnaround time, etc.) \[[@CR5]\].

The autoantibody profiling of AIDs patients provided by these systems may be useful for following the concentration of specific autoantibodies, which may display different trends over time, both for diagnostic and prognostic purposes. This is the case, for instance, of celiac disease and anti-phospholipid syndrome which are characterized by the presence of multiple autoantibodies of different isotypes. Nowadays, multiplexed technology has achieved high analytical accuracy and provides results comparable to, if not superior to, the manual and automated monoplex technologies \[[@CR42], [@CR43]\].

The autoimmunology laboratory of the near future {#Sec5}
================================================

The referred changes have altered the scenario and strongly characterized the evolution of the immunology laboratory. But what implications do these new arrangements have for the future?

*Avoiding the Ulysses syndrome for the patients* Because the results of antibody tests can be available in a few hours, it can be expected that clinical reasoning will occur much faster than now and will involve not only the rheumatologist but also many other specialists and even general practitioners. Signs of this are already visible \[[@CR44]\]. If well organized and managed, this change could have positive effects---namely, to ensure greater efficiency of the diagnostic filter, with the ability to identify during their first clinical visit those patients who need a specialist consultation. The advantages for patients, doctors and the health system overall are obvious (Table [4](#Tab4){ref-type="table"}).Table 4Automated multiplex IMA platformsInstrumentCompanyAutoantibody menu (no.)FIDISTheradiag, France25Athena Multi-LyteZeus, USA19TruePlexOrigene, USA10Bioplex 2200Bio-Rad, USA28MicrozymeImmunoConcepts, USA10Ig-PlexSQI Diagnostics, Canada22

*Reducing analytical variability of autoantibody tests* Another prediction is that measurement of the concentration of autoantibodies, which is still poorly standardized, will become more and more accurate. Subjective methods and semi-quantitative techniques will be replaced by more objective assays and with greater precision, reducing the analytical variability to levels similar to those of other immunoassays. ELISA methods will disappear and blot methods will evolve to provide quantitative results. Measurement of therapeutic antibody levels for follow-up and customization of treatments will become increasingly popular. Costs will drop and autoimmune diagnostics will become part of the clinical profile for early and differential diagnosis.

In conclusion, 20 years after the statements of the prophets about the changes occurring in the management and organization of the clinical immunology laboratory, automation, integration and consolidation allow now for the alignment of the laboratory of autoimmune diseases to other specialized sectors within the general clinical laboratory. This improvement will enable greater harmonization of laboratory autoimmune tests, greater accuracy of test results, and a better outcome for patients with autoimmune diseases.
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